CD39 Mouse anti-Human, Brilliant Violet 421, Clone: TU66 (also known as Tü 66, Tü66), BD
Mouse Monoclonal Antibody
Manufacturer: BD Biosciences 563679
The TU66 monoclonal antibody reacts with human CD39 also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) an ectoenzyme that degrades ATP to AMP. It is a member of the family of ectonucleoside triphosphate dihydrolases (E-NTPDases) known to be involved in regulation of extracellular nucleotide catabolism, controlling the extracellular nucleoside triphosphate pool (NTP). CD39 is expressed on a subset of T cells, B cells and dendritic cells with weak staining of monocytes and granulocytes. Recently, CD39 has been found to be expressed primarly by immune-suppressive Foxp3(+) regulatory T (Treg) cells in both human and mice. In humans, CD39 is restricted to a subset of Foxp3+ regulatory effector/memory-like T cells. In mice, the enzyme is present on most if not all CD4+CD25+ cells and CD39 expression is driven by Foxp3. It is thought that CD39 allows Treg cells to enter inflamed areas where high levels of ATP are present.
The antibody was conjugated to BD Horizon™ BV421 which is part of the BD Horizon™ Brilliant Violet™ family of dyes. With an Ex Max of 407-nm and Em Max at 421-nm, BD Horizon™ BV421 can be excited by the violet laser and detected in the standard Pacific Blue™ filter set (eg, 450/50-nm filter). BD Horizon™ BV421 conjugates are very bright, often exhibiting a 10 fold improvement in brightness compared to Pacific Blue™ conjugates.
|TU66 (also known as Tü 66, Tü66)|
|ENTPD1; NTPDase-1; Ecto-ATPase 1; Ecto-ATPDase 1|
|Brilliant Violet 421|
|Aqueous buffered solution containing BSA and ≤0.09% sodium azide.|
|Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok